Abstract
Objective:
The aim was to assess growth velocity (GV) during human recombinant growth hormone (hGH) treatment of children with multiple pituitary hormone deficiency (MPHD) caused by pituitary stalk interruption syndrome (PSIS) and to analyze the characteristics of patients that attained normal adult heights.
Methods:
Data from 74 (16 female) children with MPHD caused by PSIS with GH, thyroid stimulating hormone, gonadotropin and adrenocorticotropic hormone deficiencies were collected. Subjects were divided into groups: 12 pre-pubescent females (Female-Group) and 36 pre-pubescent males (Male-Group 1). The remaining 22 males were further sub-divided into two groups (Male-Group 2 and Male-Group 3) according to the initiation of gonadotropin replacement treatment, based on bone age and height.
Results:
No differences in change in height standard deviation score (△HtSDS) and GV were observed at different time points of hGH treatment between the Female-Group and Male-Group 1 (p>0.05). GV was significantly greater in the first year of hGH therapy than in subsequent years: Female-Group p=0.011; Male-Group 1 p<0.001; Male-Group 2 p=0.005; and Male-Group 3 p=0.046. Adult height was achieved by 23 (19 males and 4 females) patients. The total gain in height positively correlated with the GV during the first year (r=0.626, p<0.001).
Conclusion:
GV during hGH treatment were similar amongst pre-pubescent males and females with MPHD caused by PSIS. GV during the first year of hGH treatment appears to be an effective predictor of final height in patients with MPHD caused by PSIS.
Keywords: Pituitary stalk interruption syndrome, growth velocity, human growth hormone treatment, adult height
Read the full text
7 sections · 4 figures · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Cerbone M, Dattani MT. Progression from isolated growth hormone deficiency to combined pituitary hormone deficiency. Growth Horm IGF Res 2017;37:19-25. Epub 2017 Oct 19
Romero CJ, Nesi-Franca S, Radovick S. The molecular basis of hypopituitarism. Trends Endocrinol Metab 2009;20:506-516. Epub 2009 Oct 23
Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E. Hypopituitarism. Lancet 2007;369:1461-1470.
Haim-Pinhas H, Kauli R, Lilos P, Laron Z. Growth, development, puberty and adult height of patients with congenital multiple pituitary hormone deficiencies. Growth Horm IGF Res 2016;27:46-52. Epub 2016 Feb 19
Wang F, Han J, Shang X, Li G. Distinct pituitary hormone levels of 184 Chinese children and adolescents with multiple pituitary hormone deficiency: a single-centre study. BMC Pediatr 2019;19:441.
Fujisawa I, Kikuchi K, Nishimura K, Togashi K, Itoh K, Noma S, Minami S, Sagoh T, Hiraoka T, Momoi T, et al. Transection of the pituitary stalk: development of an ectopic posterior lobe assessed with MR imaging. Radiology 1987;165:487-489.
Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:737-747. Epub 2016 Nov 4
Caicedo A, Rosenfeld R. Challenges and future for the delivery of growth hormone therapy. Growth Horm IGF Res 2018;38:39-43. Epub 2017 Dec 17
Harrington J, Palmert MR. Clinical review: Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. J Clin Endocrinol Metab 2012;97:3056-3067. Epub 2012 Jun 20
Segal TY, Mehta A, Anazodo A, Hindmarsh PC, Dattani MT. Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J Clin Endocrinol Metab 2009;94:780-785. Epub 2008 Nov 18
Li H, Ji CY, Zong XN, Zhang YQ. Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi 2009;47:493-498.
Wang Q, Jiang W, Li G, Tang L, Hu Y. Comparison of therapeutic response to gonadotropin therapy between chinese male adolescents and young adults with hypogonadotropic hypogonadism caused by pituitary stalk interruption. Horm Metab Res 2014;46:668-673. Epub 2014 May 27
Savendahl L, Blankenstein O, Oliver I, Christesen HT, Lee P, Pedersen BT, Rakov V, Ross J. Gender influences short-term growth hormone treatment response in children. Horm Res Paediatr 2012;77:188-194. Epub 2012 Apr 12
Lee JH, Kim SK, Lee EK, Ahn MB, Kim SH, Cho WK, Cho KS, Jung MH, Suh BK. Factors affecting height velocity in normal prepubertal children. Ann Pediatr Endocrinol Metab 2018;23:148-153. Epub 2018 Sep 28
Smuel K, Kauli R, Lilos P, Laron Z. Growth, development, puberty and adult height before and during treatment in children with congenital isolated growth hormone deficiency. Growth Horm IGF Res 2015;25:182-188. Epub 2015 May 12
Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab 2016;30:749-755. Epub 2016 Nov 4
Devesa J, Almenglo C, Devesa P. Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth? Clin Med Insights Endocrinol Diabetes 2016;9:47-71.
El Chehadeh S, Bensignor C, de Monleon JV, Mejean N, Huet F. The pituitary stalk interruption syndrome: endocrine features and benefits of growth hormone therapy. Ann Endocrinol (Paris) 2010;71:102-110. Epub 2009 Dec 30
Ranke MB, Lindberg A; KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95:1229-1237. Epub 2010 Jan 22
de Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:925-931. Epub 2006 Dec 19
Ranke MB, Lindberg A, Ferrandez Longas A, Darendeliler F, Albertsson-Wikland K, Dunger D, Cutfield WS, Tauber M, Wilton P, Wollmann HA, Reiter EO; KIGS International Board. Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 2007;61:105-110.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584-3590.
Cohen LE. Idiopathic short stature: a clinical review. JAMA 2014;311:1787-1796.
Schena L, Meazza C, Pagani S, Paganelli V, Bozzola E, Tinelli C, Buzi F, Bozzola M. Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children. J Pediatr Endocrinol Metab 2017;30:197-201.


